Shenzhen-based Carbon Medical Technology Co., Ltd has reportedly raised over RMB 100 million (USD 13.9 million) in a Series A financing round, led by Cowin Capital with contributions from returning investor Jinding Capital. The funds will be directed towards enhancing product pipeline research and development (R&D), clinical and commercial layout, hospital access for products, training facility construction, and promotion of new technologies.
Expanding Non-Vascular Interventional Therapy Capabilities
Founded in 2018, Carbon Med is dedicated to non-vascular interventional therapy, having established R&D centers, GMP facilities, and medical training centers. The company has conducted over 1,000 clinical surgeries in China and formed dozens of clinical program partnerships. This funding round will significantly bolster Carbon Med’s efforts to advance its interventional therapy solutions and expand its market presence.
Innovative Medical Imaging Technology
Carbon Med’s VENUS Image fusion function is a standout technology that integrates static CT/MR sequences with dynamic ultrasound in real time, presenting 3D and 2D organ anatomical structures intuitively. This technology efficiently and conveniently assists doctors in locating lesions, planning puncture paths, and quickly guiding the accurate establishment of intervention channels and target biopsies. The VENUS system fills a significant gap in high-end technology within China’s medical imaging industry, offering a cutting-edge solution for precise and effective interventional procedures.-Fineline Info & Tech
